RoActemra 162 mg solution for injection in pre-filled pen.
Sponsors
Karolinska University Hospital, Abbvie Deutschland GmbH & Co. KG, Centre Hospitalier Universitaire De Dijon, IRCCS Istituto Giannina Gaslini, Assistance Publique Hopitaux De Paris
Conditions
Giant Cell ArteritisJuvenile idiopathic arthritisPatients with GPA and inadequate response to standard of care therapy defined as an inadequate response to either a combination of glucocorticoids plus cyclophosphamide AND/OR a combination of glucocorticoids plus rituximab.Patients with histologically (or via cytology) confirmed cancer that develop arthritis secondary to treatment with immune checkpoint inhibitors.juvenile idiopathic arthritis
Phase 2
Phase 3
TocilizuMab discontinuAtion in GIant Cell Arteritis
Active, not recruitingCTIS2023-505515-21-00
Start: 2024-04-02Target: 120Updated: 2025-11-07
A multicenter, randomized open-label study to assess the efficacy, safety, and pharmacokinetics of upadacitinib with a tocilizumab reference arm in subjects from 1 year to less than 18 years old with active systemic juvenile idiopathic arthritis.
RecruitingCTIS2022-501599-25-00
Start: 2024-03-19Target: 33Updated: 2025-11-24
SATELITE - Salvage Therapy for Patients with Inadequate Response to Standard of Care Therapy in Granulomatosis with Polyangiitis
RecruitingCTIS2024-516687-28-00
Start: 2025-06-06Target: 42Updated: 2024-11-19